CO6890074A2 - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Info

Publication number
CO6890074A2
CO6890074A2 CO13233113A CO13233113A CO6890074A2 CO 6890074 A2 CO6890074 A2 CO 6890074A2 CO 13233113 A CO13233113 A CO 13233113A CO 13233113 A CO13233113 A CO 13233113A CO 6890074 A2 CO6890074 A2 CO 6890074A2
Authority
CO
Colombia
Prior art keywords
tfpi
monoclonal antibodies
antibodies against
tissue factor
pathway inhibitor
Prior art date
Application number
CO13233113A
Other languages
English (en)
Spanish (es)
Inventor
Zhuozhi Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6890074(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CO6890074A2 publication Critical patent/CO6890074A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13233113A 2011-04-01 2013-10-01 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) CO6890074A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
CO6890074A2 true CO6890074A2 (es) 2014-03-10

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13233113A CO6890074A2 (es) 2011-04-01 2013-10-01 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR101995302B1 (enExample)
CN (2) CN107090046A (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA3068997A1 (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA201991704A3 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY190951A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039B1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG193594A1 (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
ES2722824T3 (es) * 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
CN113788897A (zh) 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US11279771B2 (en) * 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
MX388251B (es) * 2015-02-25 2025-03-19 Mogam Inst Biomedical Res Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
ES2722824T3 (es) * 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
US20220041752A1 (en) 2022-02-10
JP6170903B2 (ja) 2017-07-26
CA2831907A1 (en) 2012-10-04
WO2012135671A2 (en) 2012-10-04
PH12013502039A1 (en) 2013-12-16
HK1243426A1 (zh) 2018-07-13
IL274686B (en) 2021-09-30
JP2014511685A (ja) 2014-05-19
SG193594A1 (en) 2013-10-30
CA3068997A1 (en) 2012-10-04
CL2013002811A1 (es) 2014-02-28
WO2012135671A3 (en) 2012-12-13
MX2013011218A (es) 2013-10-17
GT201300229A (es) 2014-11-13
EA201301107A1 (ru) 2014-11-28
AU2019201814A1 (en) 2019-04-04
SI2694544T1 (sl) 2019-06-28
EA034214B1 (ru) 2020-01-17
US20180194857A1 (en) 2018-07-12
CN103797030B (zh) 2017-05-31
US20190194353A1 (en) 2019-06-27
ES2722824T3 (es) 2019-08-19
EP2694544A2 (en) 2014-02-12
EA201991704A3 (ru) 2020-06-30
AU2012236296A1 (en) 2013-10-24
CN103797030A (zh) 2014-05-14
ZA201308169B (en) 2016-03-30
PH12013502039B1 (en) 2013-12-16
CU20130128A7 (es) 2014-03-26
RS58633B1 (sr) 2019-05-31
BR112013025376A2 (pt) 2017-07-25
EP2694544A4 (en) 2015-03-25
IL228633A0 (en) 2013-12-31
IL283829A (en) 2021-07-29
CR20130499A (es) 2013-10-24
JP2017113019A (ja) 2017-06-29
US20170107298A1 (en) 2017-04-20
SG10201602606UA (en) 2016-04-28
KR20190079698A (ko) 2019-07-05
EA201991704A2 (ru) 2020-03-31
IL228633B (en) 2018-03-29
IL274686A (en) 2020-06-30
JP2021019619A (ja) 2021-02-18
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
NZ615969A (en) 2016-01-29
PH12019500439A1 (en) 2020-10-12
HRP20190467T1 (hr) 2019-05-03
UA113623C2 (uk) 2017-02-27
ECSP13012913A (es) 2014-02-28
CA2831907C (en) 2020-03-24
EP2694544B1 (en) 2019-01-23
DK2694544T3 (en) 2019-04-15
HUE042706T2 (hu) 2019-07-29
PL2694544T3 (pl) 2019-07-31
PE20141149A1 (es) 2014-08-28
LT2694544T (lt) 2019-04-25
US20140294832A1 (en) 2014-10-02
PH12019500441A1 (en) 2020-10-12
IL257145A (en) 2018-03-29
JP6363747B2 (ja) 2018-07-25
TR201905101T4 (tr) 2019-05-21
KR20140019428A (ko) 2014-02-14
JP2018172411A (ja) 2018-11-08
KR101995302B1 (ko) 2019-07-02
CN107090046A (zh) 2017-08-25
DOP2013000218A (es) 2013-11-15
MY165499A (en) 2018-03-27
CY1121538T1 (el) 2020-05-29
PT2694544T (pt) 2019-04-02
AU2017203105A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
IL283829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL277391A (en) Monoclonal antibodies are effective against tissue factor pathway inhibitor (TFPI)
LTPA2019011I1 (lt) CGRP antikūnai
IL221408B (en) Monoclonal antibodies against c-met
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
PL3342786T3 (pl) Przeciwciało przeciwko dll3
DK2580243T3 (da) Antibodies against human cd38
DK2812341T3 (da) C-terminale hsp90-inhibitorer
DK2521736T3 (da) Humaniserede antistoffer
DK2651436T3 (da) Mycobakterie antigen sammensætning.
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
BR112013025761A2 (pt) inibidores de hsp90
IL258914A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
ES1073760U8 (es) Fuente refrigerada.
FI9400U1 (fi) Puunkorjuulaite
FI9365U1 (fi) Halkaisulaite
ITUD20120133A1 (it) "dispositivo di illuminazione"
UA20571S (uk) Пляшка